LobbyingExela Pharma Sciences lobbying by quarter
Exela Pharma Sciences's latest lobbying report covers Q2 2026, at $27K. The four quarters Q4 2025–Q3 2026 total $192K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Manufacturing.
Exela Pharma Sciences
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $192K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $78K | 2 |
| Q1 2023 | $78K | 2 |
| Q2 2023 | $78K | 2 |
| Q3 2023 | $78K | 2 |
| Q4 2023 | $138K | 2 |
| Q1 2024 | $108K | 2 |
| Q2 2024 | $108K | 2 |
| Q3 2024 | $108K | 2 |
| Q4 2024 | $108K | 1 |
| Q1 2025 | $138K | 1 |
| Q2 2025 | $138K | 1 |
| Q3 2025 | $138K | 1 |
| Q4 2025 | $138K | 1 |
| Q1 2026 | $27K | 1 |
| Q2 2026 | $27K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$480K · 15 reports
- Manufacturing$480K · 15 reports
- Medical research and clinical labs$480K · 15 reports
- Pharmacy$48K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Office of Administration6 reports
Firms it paid
| Firm | ||
|---|---|---|
| Old North Strategies | $1.5M | 15 quarters |
| Broydrick & Associates | $0 | 8 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JOSEPH WAYNE KING ii | Former Dep. Chief of Staff Congressman Mark Meadows & former Sr. Advisor Dr. Greg Murphy | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Old North Strategies | $27K |
| 04/30for Q1 | Old North Strategies | $27K |
| 01/20for Q4 2025 | Old North Strategies | $138K |
| 25/10/25for Q3 2025 | Old North Strategies | $138K |
| 25/07/16for Q2 2025 | Old North Strategies | $138K |
| 25/04/10for Q1 2025 | Old North Strategies | $138K |
| 25/01/01for Q4 2024 | Old North Strategies | $108K |
| 24/10/21for Q3 2024 | Broydrick & Associates | Under $5,000 |
| 24/10/10for Q3 2024 | Old North Strategies | $108K |
| 24/07/20for Q2 2024 | Broydrick & Associates | Under $5,000 |
| 24/07/01for Q2 2024 | Old North Strategies | $108K |
| 24/04/20for Q1 2024 | Broydrick & Associates | Under $5,000 |
| 24/04/12for Q1 2024 | Old North Strategies | $108K |
| 24/01/17for Q4 2023 | Broydrick & Associates | Under $5,000 |
| 24/01/10for Q4 2023 | Old North Strategies | $138K |
| 24/01/10for Q4 2023 | Old North Strategies | $78K |
| 23/10/17for Q3 2023 | Broydrick & Associates | Under $5,000 |
| 23/10/06for Q3 2023 | Old North Strategies | $78K |
| 23/07/21for Q2 2023 | Old North Strategies | $78K |
| 23/07/19for Q2 2023 | Broydrick & Associates | Under $5,000 |